Kopran Past Earnings Performance
Past criteria checks 5/6
Kopran has been growing earnings at an average annual rate of 5.5%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 10.9% per year. Kopran's return on equity is 10.6%, and it has net margins of 8.3%.
Key information
5.5%
Earnings growth rate
2.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 10.9% |
| Return on equity | 10.6% |
| Net Margin | 8.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kopran makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,360 | 529 | 565 | 0 |
| 30 Jun 24 | 6,370 | 593 | 530 | 0 |
| 31 Mar 24 | 6,146 | 510 | 543 | 0 |
| 31 Dec 23 | 5,789 | 404 | 555 | 0 |
| 30 Sep 23 | 5,780 | 315 | 536 | 0 |
| 30 Jun 23 | 5,424 | 224 | 526 | 0 |
| 31 Mar 23 | 5,510 | 272 | 519 | 0 |
| 31 Dec 22 | 5,434 | 367 | 486 | 0 |
| 30 Sep 22 | 5,172 | 498 | 487 | 0 |
| 30 Jun 22 | 5,278 | 623 | 466 | 0 |
| 31 Mar 22 | 4,775 | 610 | 449 | 0 |
| 31 Dec 21 | 4,746 | 586 | 440 | 0 |
| 30 Sep 21 | 4,548 | 542 | 416 | 0 |
| 30 Jun 21 | 4,463 | 537 | 409 | 0 |
| 31 Mar 21 | 4,918 | 616 | 398 | 0 |
| 31 Dec 20 | 4,393 | 514 | 392 | 0 |
| 30 Sep 20 | 4,274 | 420 | 389 | 0 |
| 30 Jun 20 | 3,962 | 310 | 364 | 0 |
| 31 Mar 20 | 3,595 | 210 | 394 | 0 |
| 31 Dec 19 | 3,718 | 239 | 410 | 0 |
| 30 Sep 19 | 3,771 | 284 | 411 | 0 |
| 30 Jun 19 | 3,815 | 271 | 405 | 0 |
| 31 Mar 19 | 3,579 | 240 | 397 | 0 |
| 31 Dec 18 | 3,558 | 215 | 378 | 0 |
| 30 Sep 18 | 3,447 | 204 | 367 | 0 |
| 30 Jun 18 | 3,240 | 206 | 363 | 0 |
| 31 Mar 18 | 3,133 | 205 | 347 | 0 |
| 31 Dec 17 | 3,113 | 262 | 375 | 0 |
| 30 Sep 17 | 2,943 | 237 | 363 | 0 |
| 30 Jun 17 | 2,977 | 237 | 366 | 0 |
| 31 Mar 17 | 3,188 | 199 | 338 | 0 |
| 31 Dec 16 | 2,930 | 197 | 313 | 0 |
| 30 Sep 16 | 2,920 | 130 | 319 | 0 |
| 30 Jun 16 | 2,950 | 122 | 303 | 0 |
| 31 Mar 16 | 2,963 | 107 | 304 | 0 |
| 31 Mar 15 | 3,257 | -391 | 314 | 0 |
| 31 Mar 14 | 3,028 | 172 | 456 | 0 |
Quality Earnings: 524280 has high quality earnings.
Growing Profit Margin: 524280's current net profit margins (8.3%) are higher than last year (5.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524280's earnings have grown by 5.5% per year over the past 5 years.
Accelerating Growth: 524280's earnings growth over the past year (67.8%) exceeds its 5-year average (5.5% per year).
Earnings vs Industry: 524280 earnings growth over the past year (67.8%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 524280's Return on Equity (10.6%) is considered low.